ArticleHealth science reports2023
Higher serum interleukin-12 levels are associated with the pathophysiology of major depressive disorder: A case-control study results.
Article in Health science reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Inflammatory biomarkers and oral microbiome alterations in depression and anxiety disorders: a systematic review.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry · 2026Pooled it
- The relationship between disgust sensitivity and serum cytokine levels in non-pregnant women: a generalization of previous results on pregnant population.Brain, behavior, & immunity - health · 2026Article
- Antibody-conjugated species-sorted single-walled carbon nanotubes for multiplexed cytokine sensing.Communications materials · 2026Article
- Multiplexed Molecularly-Specific SWCNT Cytokine Sensing is Enabled and Enhanced by Amine-Functionalized DNA Aqueous Two-Phase Extraction.bioRxiv : the preprint server for biology · 2025Article
- Serum TNFα and IL-17A levels may predict increased depressive symptoms: findings from the Shika Study cohort project in Japan.BioPsychoSocial medicine · 2024Article
- Evaluation of serum interleukin-12 and interleukin-4 as potential biomarkers for the diagnosis of major depressive disorder.Scientific reports · 2024Article
- Serum levels of interleukin-33 and mesencephalic astrocyte derived neurotrophic factors in patients with major depressive disorder: a cross-sectional comparative design.BMC psychiatry · 2024Article
- Evaluation of serum MIP-1β and MCP-2 levels in major depressive disorder: A case-control study.PloS one · 2024Article
- Altered IL-3 and lipocalin-2 levels are associated with the pathophysiology of major depressive disorder: a case-control study.BMC psychiatry · 2023Article
- Evaluation of serum interleukin-1 receptor antagonist levels in major depressive disorder: A case-control study.Health science reports · 2023Article
- Article
- Higher serum interleukin-12 levels are associated with the pathophysiology of major depressive disorder: A case-control study results.Health science reports · 2023Article
- Association of reduced serum EGF and leptin levels with the pathophysiology of major depressive disorder: A case-control study.PloS one · 2023Article
- Elevated Serum IL-2 Levels are Associated With Major Depressive Disorder: A Case-Control Study.Clinical pathology (Thousand Oaks, Ventura County, Calif.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Major depressive disorder (MDD) is the fourth biggest health-related concern that dramatically impacts individuals' mental and physical health. Alteration of serum proinflammatory cytokine levels may take part in the development and progression of MDD. We aimed to explore and compare the role of interleukin-12 (IL-12) in MDD patients and healthy controls (HCs) and its involvement with the disease severity. Methods: The present study included 85 patients and 87 age-sex matched HCs. A qualified psychiatrist utilized the diagnostic and statistical manual of mental disorders, fifth edition (DSM-5) criteria to diagnose patients and evaluate HCs. We applied the Ham-D rating scale to measure the severity of depression. Serum IL-12 levels were measured using ELISA kits. Results: We observed a notable increase in the serum levels of IL-12 in MDD patients compared to HCs (164.27 ± 10.18 pg/ml and 82.55 ± 4.40 pg/ml; Conclusion: The current study findings support that IL-12 levels are involved with the pathogenesis and inflammatory process in MDD. At the same time, this involvement may make this cytokine eligible for the risk evaluation of MDD. However, we recommend further interventional studies to explore more accurate associations between IL-12 and depressive disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.